Supply Chain

Meridian Medical Technologies, which manufacturers EpiPens for Mylan, on Friday expanded its global recall of the life-saving devices to include the U.S. market, reports Reuters.

Several major drugmakers have thrown a wrench into the typical drug pricing system this week by setting lower than normal prices for two newly-approved drugs, reports Bloomberg.

A Swiss logistics firm will use drones to transport laboratory samples between hospitals as a regular service by 2018, reports The Verge.

Here are the four latest drugs approved by the Food and Drug Administration this week.

The Food and Drug Administration on Tuesday approved Genentech's drug Ocrevus for adults with severe forms of multiple sclerosis.

Here are seven articles published by Becker's Hospital Review this week highlighting Amazon's first drone delivery in the U.S., strategies to limit hidden costs associated with prepackaged supplies and notable device recalls from 2016, among other topics.

George Yancopoulos, MD, PhD, president and chief scientific officer of Regeneron Pharmaceuticals, condemned President Donald Trump's proposed budget cuts for HHS, warning that withdrawing investments for science and health research poses risks for the health of future generations, according to…

Bill Ackman, founder and CEO of New York City-based Pershing Square Capital Management, called his investment in Valeant Pharmaceuticals International a "huge mistake" in an annual letter to investors," reports Bloomberg.

Scott Gottlieb, MD, on Tuesday filed an ethics disclosure form with HHS, highlighting measures he would take to distance himself from the drug industry if confirmed to lead the Food and Drug Administration, reports Reuters.

Mylan's $465 million proposed settlement with CMS may not cover the amount of money it allegedly saved by improperly classifying EpiPens as a generic drug, according to research published Monday in JAMA Internal Medicine.